Sepsis Fells Another Contender
Agennix's Phase II/III Study Halted by Mortality Finding
LONDON – The challenging indication of severe sepsis has confounded yet another attempt to develop a registered treatment, with the curtailment of the Phase II/III trial of Agennix AG's talactoferrin.
